Research map: Targeting Epstein-Barr Virus for Cancer Vaccines: Recent Advances and Future Directions
Back to the article
Papers in this map
A gB nanoparticle vaccine elicits a protective neutralizing antibody response against EBV
· Cong Sun · 2023 · 77 citations · Cited by this paper
In vivo intratumoral heterogeneity in a dish: scalable forebrain organoid models of embryonal brain tumors for high‐throughput personalized drug discovery
· 2025 · Related
The Safety and Immunological Effects of rAd5-EBV-LMP2 Vaccine in Nasopharyngeal Carcinoma Patients: A Phase I Clinical Trial and Two-Year Follow-Up
· Yongfeng Si · 2016 · 51 citations · Cited by this paper
Anbenitamab in combination with chemotherapy in patients with HER2‐positive gastric or gastroesophageal junction carcinoma who failed previous therapy containing trastuzumab: a multicenter, phase II study (KC‐WISE 01)
· 2025 · Related
A lipid-based LMP2-mRNA vaccine to treat nasopharyngeal carcinoma
· Mengran Guo · 2023 · 42 citations · Cited by this paper
A practical overview and statistical analysis of interval‐censored data in cancer
· 2025 · Related
mRNA‐based Vaccines Targeting the T‐cell Epitope‐rich Domain of Epstein Barr Virus Latent Proteins Elicit Robust Anti‐Tumor Immunity in Mice
· Ge‐Xin Zhao · 2023 · 38 citations · Cited by this paper
The Roles of Protein S -Palmitoylation in Cancers: From Dynamic Modulation to Therapeutic Potential
· 2026 · Related
Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit
· Emily Pauline Nickles · 2021 · 29 citations · Cited by this paper
WTAP-Mediated Glutaminase Splicing Bias Suppresses Ferroptosis in Hepatocellular Carcinoma
· 2026 · Related
EBV latent membrane proteins promote hybrid epithelial-mesenchymal and extreme mesenchymal states of nasopharyngeal carcinoma cells for tumorigenicity
· Nannan Zhu · 2021 · 28 citations · Cited by this paper
Proliferation and Apoptosis Adaptor Protein 15 (PEA15), a Potential Oncogenic Regulator of VHL and HIF1A Identified through Proteomic Analysis in Hepatocellular Carcinoma
· 2026 · Related
Structural basis of Epstein-Barr virus gp350 receptor recognition and neutralization
· Cong Sun · 2025 · 16 citations · Cited by this paper
CD24 is a promising immunotherapeutic target for enhancing efficacy of third‐generation EGFR‐TKIs on EGFR‐mutated lung cancer
· 2025 · Related
A broadly protective antibody targeting gammaherpesvirus gB
· Cong Sun · 2026 · 11 citations · Cited by this paper
Neoadjuvant chemoradiotherapy with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer: 5‐year update of the CinClare trial
· 2025 · Related
Safety, tolerability, and immunogenicity of WGc-043 in subjects with EBV-positive cancers: Results from an investigator-initiated trial.
· Xingchen Peng · 2024 · 9 citations · Cited by this paper
HMGB3 promotes brain metastasis of lung adenocarcinoma by recruiting SSBP1 for nuclear translocation to remodel mitochondrial metabolism
· 2025 · Related
811MO An exploratory study to assess the safety, immunogenicity, and preliminary anti-tumor activity of the EBV mRNA vaccine (WGc-043 injection) in patients with NK/T cell lymphoma
· Xueqiang Peng · 2024 · 1 citation · Cited by this paper
Camrelizumab Plus Nab-paclitaxel in Patients with Previously Treated Advanced Urothelial Carcinoma: A Multicenter Phase II Study
· 2026 · Related
Source: OpenAlex (CC0)